Sensorimotor gating, a neural process severely disrupted in patients with schizophrenia, can be measured by assessing prepulse inhibition (PPI) of acoustic startle responses. PPI is disrupted in experimental animals by stimulation of D 2 -like dopamine receptors in the nucleus accumbens (NAc). We examined the effect of repeated treatment with a selective dopamine D 2 -like receptor agonist, quinpirole, and characterized the molecular substrates of the resulting PPI adaptation. Animals were treated once daily for 10 or 28 consecutive days with quinpirole (0.0, 0.05, 0.1, or 0.3 mg/kg, s.c.), and the effect on PPI was assessed throughout the treatment period. PPI was reduced after acute quinpirole administration, but gradually increased with repeated treatment. Quinpirole-induced PPI disruption was attenuated after 10 days of treatment at lower doses, but complete recovery was not apparent until the treatment period was extended to 28 days. Since chronic drug exposure can alter the dopamine system, we sought to characterize the effects of repeated quinpirole treatment on G proteins coupled to D 2 -like receptors in the NAc. Guanosine 5Ј-O-(3-[
doses, but complete recovery was not apparent until the treatment period was extended to 28 days. Since chronic drug exposure can alter the dopamine system, we sought to characterize the effects of repeated quinpirole treatment on G proteins coupled to D 2 -like receptors in the NAc. Guanosine 5Ј-O- (3-[ 35 S]thiotriphosphate) ([ 35 S]GTP␥S) binding and Western blot analysis revealed that repeated quinpirole treatment had no effect on NAc D 2 -like receptor G protein function or G protein levels. These data indicate that repeated activation of D 2 -like receptors by quinpirole produces tolerance in the absence of receptor or G protein changes, suggesting that the locus of dopaminergic adaptation might be at the intracellular level.
Animal models of sensorimotor gating are used to study the aberrant neurotransmitter systems underlying psychotic disorders. Defined as the neural process responsible for the integration and processing of sensory information, sensorimotor gating is deficient in patients with schizophrenia (Braff et al., 1978) . This phenotype can be quantitatively assessed in various species by measuring prepulse inhibition (PPI) of the acoustic startle response (Swerdlow et al., 1991) , which is the reduction in response when a startling pulse stimulus is preceded by a weak prepulse stimulus.
The neural substrate for PPI modulation includes the mesocorticolimbic dopamine system (Swerdlow and Geyer, 1998; Swerdlow et al., 2001) , especially D 2 -like dopamine receptors in the nucleus accumbens (NAc). When administered systemically, both direct and indirect dopamine agonists disrupt PPI in experimental animals (Mansbach et al., 1988) , as do selective D 2 -like receptor agonists such as quinpirole and 7-hydroxy-dipropylaminotetralin (7-OH-DPAT) (Peng et al., 1990; Varty and Higgins, 1998) . The involvement of NAc D 2 -like receptors in PPI regulation was confirmed by site-specific infusion of quinpirole into the NAc, which elicited PPI disruption (Wan and Swerdlow, 1993) .
Although the effect of acute dopamine agonist treatment on PPI is well defined, there are contradictory reports on the effect of chronic drug treatment. Repeated administration of amphetamine, an indirect-acting dopamine agonist, or apomorphine, a nonselective dopamine agonist, reportedly causes sensitization of PPI disruptive effects (Zhang et al., 1998; Martin-Iverson, 1999) . In contrast, repeated administration of the same drugs also has been observed to attenuate or eliminate PPI disruption compared with acute treatment (Mansbach et al., 1988; Druhan et al., 1998; Feifel et al., 2002) , as does repeated cocaine treatment (Byrnes and Hammer, 2000) . The reason for these behavioral differences is unclear; however, variations in methodology or in animal substrains might contribute to the inconsistent effects. Since the D 2 -like receptor is preferentially implicated in PPI reg-ulation, the effect of repeated stimulation might be more clearly defined by the use of a more selective receptor agonist. Therefore, we sought to examine PPI adaptation after repeated treatment with the selective D 2 -like receptor agonist, quinpirole.
In addition, we sought to characterize the substrates underlying PPI adaptation following repeated quinpirole treatment by assessing putative changes in D 2 -like receptor G protein function. NAc D 2 -like receptors are coupled to G i and G o proteins (Stoof and Kebabian, 1981) , which are critical for PPI modulation (Culm et al., 2003) . Chronic cocaine treatment, which attenuates PPI disruption (Byrnes and Hammer, 2000) , decreases pertussis toxin-mediated ADP-ribosylation of G i␣ and G o␣ and reduces G i␣ and G o␣ immunoreactivity in the NAc (Nestler et al., 1990 ). In contrast, repeated haloperidol treatment increases D 2 -like receptor binding and efficacy of D 2 -like receptor G protein coupling as assessed using [
35 S]GTP␥S binding (Geurts et al., 1999) , without affecting G i␣ or G o␣ levels (Meller and Bohmaker, 1996) . Therefore, we utilized dopamine-stimulated [
35 S]GTP␥S binding and immunoblots to quantify putative alterations of G proteins coupled to the D 2 -like receptor after repeated quinpirole treatment.
Materials and Methods

Experiment I
Animals and Drug Treatment. For all of the following experiments, animals were provided with food and water ad libitum while housed in a climate-controlled facility with 12-h reverse light/dark cycles (lights off at 9:00 AM). Animals were allowed to acclimate to the laboratory for 7 days before handling. All experiments were approved by the Tufts-New England Medical Center Animal Care and Use Committee and conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) weighing 250 to 300 g were habituated to handling and placed into a Startle Monitor behavioral testing chamber (HamiltonKinder LLC, Julian, CA) with 70 db ambient noise for 5 min daily on each of 2 days before testing. Animals were treated once daily for 10 consecutive days with the same dose of quinpirole (0.0, 0.05, 0.1, or 0.3 mg/kg, s.c.; Sigma/RBI, Natick, MA) in 0.9% sterile saline.
Prepulse Inhibition Testing. Startle amplitude was determined using the Startle Monitor behavioral testing system (Hamilton-Kinder, LLC) at baseline and after quinpirole treatment on days 1, 4, 7, and 10. Mean startle amplitude was measured over 100 ms following the presentation of the pulse stimulus in units of newtons. For baseline testing, each animal was exposed to 70 db ambient noise for 5 min followed by a test session consisting of the randomized presentation of 32 trials: 17 pulse trials (40 ms, 120-db pulse) and 15 prepulse trials (five each at 73, 76, and 82 db with a 20-ms prepulse given 100 ms before a 40 ms 120-db pulse). The mean acoustic startle response to pulse alone trials was used to normalize animals into various treatment groups. Starting 2 to 3 days later, the first drug challenge test session began 10 min after quinpirole treatment and consisted of the randomized presentation of 54 trials: 24 pulse trials, 10 73-db prepulse trials, 10 76-db prepulse trials, and 10 82-db prepulse trials. The average intertrial interval was 15 s and percent PPI was calculated using the following equation: 100 Ϫ [(mean prepulse response/mean pulse response) ϫ 100]; a higher percent PPI implies greater inhibition of startle response due to presentation of the prepulse. Percent PPI data calculated for each prepulse level and mean pulse response data on the first and last day of testing were analyzed by separate analyses of variance (ANOVAs) with drug treatment as a between-subject factor. Within each treatment group, percent PPI data were analyzed using ANOVA with repeated measures. Post hoc comparisons were conducted using Dunnett's test. Alpha was 0.05.
[ 35 S]GTP␥S Binding Analysis. Immediately after PPI testing on day 10, animals were decapitated, and brains were removed and rapidly frozen at Ϫ30°C in 2-methylbutane and sectioned at 16 m using a Ϫ20°C cryostat. Sections corresponding to approximately 1.7 mm anterior to bregma were collected, thaw mounted onto gelatincoated slides, and stored at Ϫ80°C for a maximum of 7 days prior to the time of the binding assay. Animals from the high dose group were not assessed because no behavioral adaptations occurred with repeated treatment.
[ 35 S]GTP␥S binding was performed as described previously (He et al., 2000) . Briefly, sections were preincubated in assay buffer (50 mM Tris-HCl, 3 mM MgCl 2 , 0.2 mM EGTA, and 100 mM NaCl, pH 7.4) for 15 min at 25°C followed by a 15-min incubation in the same buffer supplemented with 2 mM GDP (ICN, Costa Mesa, CA). Sections were then incubated in assay buffer containing 2 mM GDP and 50 pM [ 35 S]GTP␥S (PerkinElmer Life and Analytical Sciences, Boston, MA) in the absence (basal) or presence of 1, 10, and 100 M, or 1 mM dopamine (Sigma-Aldrich, St. Louis, MO) for 1 h at 25°C. The sections were washed two times for 3 min at 4°C in 50 mM Tris-HCl (pH 7.4) and briefly rinsed in distilled water. After air drying, slides were coexposed with 14 C radiostandards (ARC-146; American Radiolabeled Chemicals, St. Louis, MO) to X-ray film (Biomax MR; Eastman Kodak Company, Rochester, NY) for 4 days. Autoradiographic images were analyzed using NIH Image (developed by Wayne Rasband, NIMH; available on the Internet at http://rsb.info.nih.gov/nih-image/) to determine the relative amount of ligand binding using a calibration curve constructed in terms of microcuries per gram based on the 14 C radiostandards. Data were expressed as percent binding above basal levels. Nonlinear regression analysis was used to calculate maximal efficacy and log EC 50 values from sigmoidal doseresponse binding curves using GraphPad Prism (GraphPad Software, San Diego, CA). Maximal efficacy and log EC 50 values were compared using a one-way analysis of variance. Log EC 50 data are expressed in terms of the EC 50 and its 95% confidence interval for each treatment group (the confidence interval is symmetrical on a log scale, but asymmetrical when converted to EC 50 ).
Experiment II
Animals and Drug Treatment. Male Sprague-Dawley rats (Charles River Laboratories) weighing 250 to 300 g were habituated to handling and the behavioral test chambers for 2 days. Animals were treated once daily for 28 consecutive days with the same dose of quinpirole (0.0, 0.05, or 0.1 mg/kg). Treatment groups were normalized according to the mean acoustic startle response observed during baseline testing. The effect of chronic drug exposure on PPI was assessed on days 1, 7, 14, 21, 25, and 28. Percent PPI data calculated for each prepulse level and mean pulse response data on the first and last day of testing were analyzed by separate ANOVAs with drug treatment as a between-subject factor. Within each treatment group, PPI data were analyzed by ANOVA with repeated measures. Post hoc comparisons were conducted using Dunnett's test.
Western Blot Analysis of G i␣ and G s␣ Protein. Following PPI testing on day 28, animals were decapitated, and their brains were removed and frozen at Ϫ30°C in 2-methylbutane. A subset of brains from each treatment group were sectioned using a Ϫ20°C cryostat to a level corresponding to 1.7 mm anterior to bregma; the remaining brains were utilized for [
35 S]GTP␥S binding analysis (described below). A unilateral 2-mm wide micropunch (1-mm deep) of the NAc was obtained and homogenized in ice-cold homogenization buffer (50 mM Tris, pH 7.4, 1 mM dithiothreitol, 1 mM EGTA, 10 g/ml leupeptin, and 20 g/ml aprotinin). Homogenized tissue was centrifuged at 10,000g, and the resulting pellet was resuspended in 100 l of homogenization buffer. Protein content in tissue homogenates was jpet.aspetjournals.org calculated using a protein assay kit (Bio-Rad, Hercules, CA), and the samples were stored at Ϫ80°C before analysis.
Aliquots of tissue homogenates were separated by SDS-polyacrylamide gel electrophoresis using 12% polyacrylamide gels. Seven and 14 g of total protein were loaded per lane for G i␣ and G s␣ , respectively. All experimental samples were analyzed in duplicate. Recombinant G i␣ or G s␣ protein (Santa Cruz Biotechnology, Santa Cruz, CA) was used as calibration standards on each gel at concentrations of 50, 100, and 200 ng/well for G i␣ and 40, 80, and 160 ng/well for G s␣ . The recombinant G i␣ protein utilized migrates with a molecular weight of 42 kDa, approximately 1 kDa larger than endogenous G i␣ due to the addition of an epitope tag.
After gel electrophoresis, proteins were transferred to membranes (Immobilon-P; Millipore, Bedford, MA) then incubated overnight at 4°C in 5% blocking solution (5% dry milk, 1ϫ TBS/0.05% Tween). Membranes were incubated for 1 h at room temperature in antisera specific for either the carboxy terminus of G i␣1-3 of rat origin (1:500 dilution, C-10; Santa Cruz Biotechnology, Inc.) or the carboxy terminus of G s␣ of rat origin (1:400 dilution, C-18; Santa Cruz Biotechnology, Inc.). Blots were incubated for 1 h at room temperature in a 1:10,000 dilution of horseradish peroxidase-conjugated donkey antirabbit IgG (Pierce Biotechnology, Rockford, IL) in 1% blocking solution and washed twice in 1ϫ TBS/0.05% Tween and once in 1ϫ TBS. Immunolabeled bands were detected using chemiluminescence (ECL Plus; Amersham Biosciences, Piscataway, NJ). Quantification software (Quantity One; Bio-Rad Laboratories) was utilized to generate a standard curve of density ϫ pixel area versus nanograms of recombinant G ␣ protein. These standard curves were used to calculate the relative immunoreactivity of bands representing G i␣ with a molecular weight of 40 to 41 kDa or G s␣ with a molecular weight of 42 and 47 kDa (Self et al., 1994) . Data were compared using a one-way ANOVA.
[ 35 S]GTP␥S Binding Analysis. Immediately after PPI testing on day 28, animals were decapitated, and brain tissue was processed as described in Experiment I. Following preincubation, sections were incubated in assay buffer containing 2 mM GDP (ICN) and 50 pM [ 35 S]GTP␥S (PerkinElmer Life and Analytical Sciences) in the absence (basal) or presence of 100 M dopamine (Sigma-Aldrich) for 1 h at 25°C. Only one concentration of dopamine (100 M), which elicits maximal [
35 S]GTP␥S binding (He et al., 2000) , was utilized in this assay because the results of Experiment I revealed that repeated quinpirole treatment did not affect maximal efficacy or EC 50 values. After sections were washed, dried, and exposed to X-ray film, the relative amount of ligand binding was determined using a calibration curve based on 14 C radiostandards coexposed to film. Data were expressed as percent binding above basal. The effect of chronic quinpirole administration on basal and dopamine-stimulated [ 35 S]GTP␥S binding was assessed using one-way ANOVA. (Fig. 1) . Repeated administration of the lowest dose (0.05 mg/kg) attenuated the ability of quinpirole to reduce PPI. By day 10, PPI had increased significantly by 34 and 38% compared with day 1 following 76-and 82-db prepulses, respectively ( Fig. 1 Table 2) .
Results
PPI Adaptation after
The effect of longer drug exposure on PPI was investigated in the second experiment. Again, PPI was disrupted by acute quinpirole treatment; increasing doses of quinpirole reduced PPI on day 1 of treatment by 34 and 46% compared with vehicle treatment following 76-db prepulses [F(2,65) ϭ 4.2, p Յ 0.05] (Fig. 2) . In fact, significant PPI disruption occurred on day 1 at all prepulse levels except after 73-db prepulses in the low dose treatment group (Table 3) . PPI increased gradually with repeated quinpirole treatment (Fig. 2) . Both quinpirole doses produced full recovery of normal PPI levels by day 28, when PPI did not differ among treatment groups at any prepulse level [73-db prepulse: F(2,64) ϭ 1.1, p ϭ 0.3; 76-db prepulse: F(2,64) ϭ 0.5, p ϭ 0.6; 82-db prepulse: F(2,64) ϭ 2.4, p ϭ 0.1] and was significantly higher than day 1 after both quinpirole doses following 76-and 82-db prepulses (Table 3) . Neither acute nor 28 days of repeated quin- Fig. 1 . PPI disruption after acute quinpirole is attenuated with a 10-day treatment. Animals were treated daily for 10 consecutive days with quinpirole (0.0, n ϭ 29; 0.05, n ϭ 24; 0.1, n ϭ 24; or 0.3 mg/kg, n ϭ 23). Percent PPI (mean Ϯ S.E.M.) was calculated from data obtained using a prepulse 6 db above ambient noise level. (Table 4) .
PPI Recovery after
Effect of Repeated Quinpirole Administration on G Protein Level and Function in the NAc. There was no significant effect of 10-day quinpirole treatment on the maximum efficacy of dopamine-mediated [
35 S]GTP␥S binding nor on EC 50 values in either the NAc core or shell ( Fig. 3 and Table 5 ). For example, maximal dopamine efficacy in the NAc core after 0.05 and 0.1 mg/kg quinpirole treatment was 93 and 81% of vehicle group values, while EC 50 values decreased by 12% after the low dose and increased by 13% after the intermediate quinpirole dose.
Similarly, 28-day quinpirole exposure had no effect on dopamine-mediated [
35 S]GTP␥S binding in the NAc core or shell (Fig. 4) . Binding increased slightly in both regions after quinpirole treatment compared with vehicle treatment, but there was no significant effect of treatment on either basal (Fig. 4, inset) or dopamine-stimulated [
35 S]GTP␥S binding. The effect of 28-day quinpirole treatment on NAc G proteins was assessed further by measuring levels of G protein immunoreactivity (Fig. 5 ). There were no significant differences between treatment groups in the amount of G i␣ protein, nor were treatment effects detected in the levels of G s␣ protein (Table 6) .
Discussion
Attenuation of D 2 -Like Agonist-Induced PPI Disruption. Acute quinpirole treatment disrupted PPI in agreement with prior studies (Peng et al., 1990; Caine et al., 1995; Wan et al., 1996) , although the doses effective herein were lower than in most previous reports. This could be due to methodological differences, such as the use of slightly different prepulse levels or different drug sensitivity across rat strains and suppliers. For example, similar doses of quinpirole (0.03 and 0.1 mg/kg) fail to disrupt PPI in male SpragueDawley rats purchased from Harlan (Indianapolis, IN) (Peng et al., 1990; Caine et al., 1995; Wan et al., 1996) , but quinpirole significantly disrupts PPI in male Wistar rats at a dose of 0.01 mg/kg (Varty and Higgins, 1998) . Analogous strain and supplier-based differences in sensitivity to PPI-disruptive effects of other dopamine agonists have been documented previously (Swerdlow et al., 2000) .
After 10 days of repeated treatment, quinpirole-mediated PPI disruption was significantly attenuated by 0.05 mg/kg treatment, but not at higher doses. Higher doses of quinpirole have been reported to significantly disrupt PPI in addition to reducing mean startle responses to pulse trials (Peng et al., 1990) , as observed herein following repeated treatment with 0.3 mg/kg quinpirole. Extending the treatment period to 28 days, however, significantly increased PPI following both 0.05 and 0.1 mg/kg quinpirole doses. The time course of behavioral attenuation following repeated quinpirole treatment differed slightly between experiments. This might be the result of substrain differences, as these animals were obtained from different locations operated by the same supplier.
This reversal of PPI disruption in response to repeated exposure to a selective D 2 -like receptor agonist suggests that tolerance occurred to the effect of quinpirole. These findings are consistent with earlier studies demonstrating the development of tolerance to the disruptive effects of cocaine, amphetamine, or apomorphine upon repeated treatment (Druhan et al., 1998; Byrnes and Hammer, 2000; Feifel et al., 2002) . In fact, such PPI tolerance coexists with cocaine-induced motor sensitization (Byrnes and Hammer, 2000) , which is thought to involve D 1 -like receptor supersensitivity (Henry et al., 1998) . However, PPI tolerance was blocked by concurrent haloperidol administration (Feifel et al., 2002) , suggesting that D 2 -like receptor stimulation is critical. Furthermore, the effect of repeated quinpirole treatment has similar effects on locomotor activity; acute quinpirole dose dependently reduces locomotor activity, but such inhibition is attenuated upon repeated administration (Rowlett et al., 1995) . Thus, behavioral tolerance upon repeated treatment with dopamine agonists might be due to a selective action at D 2 -like receptors. It is possible that hepatic metabolism of quinpirole is induced by repeated treatment, perhaps leading to reduced brain exposure to the drug. No current data exist to address this possibility, which is unlikely because tolerance to PPI disruption also occurs upon repeated treatment with dopamine agonists from other chemical classes (e.g., cocaine, amphetamine, and apomorphine; Druhan et al., 1998; Byrnes and Hammer, 2000; Feifel et al., 2002) . Receptor G Protein Function Associated with PPI Tolerance. Repeated treatment with a higher quinpirole dose (i.e., 1 mg/kg) is known to down-regulate D 2 -like receptor density in the NAc (Subramaniam et al., 1992) and increase striatal dopamine synthesis and turnover (Rowlett et al., 1995; Sullivan et al., 1998; Koeltzow et al., 2003) . Furthermore, repeated cocaine treatment reduces levels of G i␣ and G o␣ protein in the NAc (Nestler et al., 1990) . Such alteration of receptors or G proteins mediating the actions of quinpirole could produce PPI tolerance. In fact, quinpirolemediated PPI disruption was reduced when NAc G i /G o proteins were functionally inactivated by pertussis toxin (Culm et al., 2003) . Therefore, we evaluated dopamine-stimulated receptor G protein function as well as G protein levels following repeated quinpirole treatment.
The functional coupling between receptors and G proteins in the NAc was investigated following repeated quinpirole treatment using [
35 S]GTP␥S binding analysis, which has been used to detect changes in receptor-effector coupling after chronic drug exposure. For example, chronic haloperidol administration increases D 2 agonist-mediated [ 35 S]GTP␥S binding to striatal membranes (Geurts et al., 1999) . This assay can be used in rat brain sections to examine regional specificity of drug effects (He et al., 2000) and a low concentration of Mg 2ϩ in the assay buffer, which preferentially excludes G s proteins (Waeber and Moskowitz, 1997) , permits selective visualization of D 2 -like receptor activity by stimulation with dopamine, as confirmed previously (Culm et al., 2003) .
Utilizing a range of dopamine concentrations, we demonstrated that 10-day quinpirole exposure did not alter receptor G protein coupling, having no significant effect on the maximum efficacy of dopamine nor on EC 50 values (Table 5) . Increasing dopamine concentrations produced a gradual increase in [ 35 S]GTP␥S binding in all treatment groups, and dopamine-stimulated [
35 S]GTP␥S binding levels approached a plateau at 100 M, as observed previously by He et al. (2000) . However, dopamine in solution can undergo autooxidation resulting in the production of reactive quinone derivatives (Slivka and Cohen, 1985) , which could interfere with [
35 S]GTP␥S binding. If so, then the absolute values Fig. 2 . Full recovery of PPI occurs after 28 days of repeated quinpirole treatment. Quinpirole was administered daily for 28 consecutive days (n ϭ 23 in each group). The effect of drug treatment on PPI was assessed on days 1, 7, 14, 21, 25, and 28. Percent PPI (mean Ϯ S.E.M.) was calculated from data obtained using a prepulse 6 db above ambient noise level. (Fig. 4) .
NAc G proteins were further investigated after a 28-day quinpirole treatment using quantitative Western blot analysis. Although repeated treatment with an indirect dopamine agonist reduced NAc G i␣ and G o␣ levels (Nestler et al., 1990) , the relatively low dose and selectivity of the D 2 -like dopamine agonist utilized herein had no effect on NAc G i␣ or G s␣ protein levels (Table 6 ). Thus, repeated treatment had no effect on either G protein level or D 2 -like receptor G protein efficacy, so it is unlikely that repeated quinpirole administration altered NAc D 2 receptor level.
Alterations in Dopaminergic Signaling. These data indicate that repeated stimulation of D 2 -like receptors using quinpirole produces behavioral tolerance to sensorimotorgating deficits in the absence of receptor or G protein changes, suggesting that the locus of dopaminergic adaptation might be at the intracellular level. In support of this hypothesis, it was recently reported that extracellular dopamine release in the NAc is similarly reduced by both acute and repeated quinpirole treatment, suggesting that repeated quinpirole does not alter presynaptic D 2 autoreceptor sensitivity and implicating postsynaptic neuroadaptations in the resulting behavioral changes (Koeltzow et al., 2003) .
Continuous exposure to G i /G o protein-coupled receptor agonists leads to supersensitivity of the cAMP signaling cascade (Thomas and Hoffman, 1987) , also known as heterologous sensitization of adenylate cyclase. For example, upregulation of the cAMP signaling pathway develops after chronic administration of opiates and cocaine Self et al., 1998) , and chronic morphine treatment increases the expression and activity of cAMPdependent protein kinase A (PKA) in the locus coeruleus (Lane-Ladd et al., 1997) . Alterations in the level of G i␣ or G s␣ are not required for heterologous sensitization (Palmer et al., 1997; Watts et al., 1999) , so the investigation of downstream targets in the cAMP pathway might provide additional insight into the mechanisms underlying the development of behavioral tolerance following repeated quinpirole exposure. Acute quinpirole treatment reduces cAMP accumulation (Johnston et al., 2002) , as well as forskolin-stimulated dopamine and cyclic adenosine 3Ј,5Ј-monophosphate-regulated phosphoprotein phosphorylation (Nishi et al., 1997) . Therefore, PPI disruption induced by acute quinpirole treatment could be related to changes in adenylate cyclase or PKA jpet.aspetjournals.org function, and the reversal of PPI disruption upon repeated treatment might be due to compensatory changes in the same enzymes. In fact, antipsychotic treatments that reduce PPI disruption (Swerdlow and Geyer, 1998 ) also alter PKA expression and function (Dwivedi et al., 2002) .
In the present study, long term D 2 -like agonist treatment was associated with the reversal of sensorimotor gating deficits, an adaptation that would be advantageous in reducing symptoms of schizophrenia. The resulting functional change in the endogenous dopamine system might have therapeutic potential for the treatment of schizophrenia. For example, the dopamine partial agonist, aripiprazole, appears to be an effective treatment that reduces both positive and negative symptoms in schizophrenia (Kane et al., 2002) . Thus, full or partial dopaminergic agonists might produce benefits by attenuating D 2 -like receptor signaling without altering receptor G protein function. Experimental samples (7 g/lane) were separated by SDS-polyacrylamide gel electrophoresis along with known amounts of recombinant G i␣ protein (50, 100, and 200 ng). Proteins were transferred to ImmobilonP membranes and blots were probed with an antibody specific for G i␣1-3 . Immunoreactive bands were detected by enhanced chemiluminescence and analyzed using BioRad Quantity One quantification software. Recombinant proteins were used to generate a standard curve, which was then utilized to calculate concentration of G i␣ in experimental samples. 
